Erratum to ‘Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients’

Le résumé fourni par la source

The publisher regrets that the affiliations for the authors in this article were incorrect at the time the article was published. They are correct as presented within this erratum. The publisher would like to apologise for any inconvenience caused. Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsESMO OpenVol. 7Issue 1PreviewDel Re et al. report that concomitant use of proton pump inhibitors (PPIs) has a detrimental effect on progression-free survival (PFS) in patients with metastatic breast cancer (mBC) treated with palbociclib.1 The authors describe a retrospective observational analysis of mBC patients treated with palbociclib, and they report that those who take PPIs for at least two-thirds of their treatment have a PFS of 14.0 months, compared to 37.9 months (P < 0.0001) in patients not taking PPIs.1 There are several critical considerations omitted in this analysis that call into question these findings and the resulting conclusions presented. Full-Text PDF Open Access

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.